ORAMED PHARMACEUTICALS INC.
ORMPNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | — | $1.3M | $2.7M | $2.7M | $2.7M |
| Operating income | −$15.1M | −$12.8M | −$15.8M | −$40.6M | −$24.2M | −$11.8M |
| Net income | $64.0M | −$19.1M | $5.5M | −$36.6M | −$23.0M | −$11.5M |
| Total assets | $230.9M | $155.3M | $220.6M | $161.6M | $177.8M | $44.6M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $199.7M | $146.3M | $163.8M | $151.8M | $166.5M | $32.9M |
| EPS (diluted) | $1.50 | $-0.48 | $0.14 | $-0.94 | $0.78 | — |
| Shares out. | 40.9M | 40.5M | 39.8M | 39.6M | 38.1M | 23.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −754.4%
- Net margin
- 3202.5%
- Return on equity
- 32.1%
- Return on assets
- 27.7%
- Return on capital (ROCE)
- −7.1%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $4.89
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- 31.7%high accruals
- Piotroski F-Score
- 2/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 1 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2026
- NT 10-Qmissed a reporting deadline ↗Jul 16, 2013
- NT 10-Kmissed a reporting deadline ↗Nov 29, 2012
- NT 10-Qmissed a reporting deadline ↗Jul 16, 2008
- NT 10-Kmissed a reporting deadline ↗Nov 29, 2007
- NT 10-Qmissed a reporting deadline ↗Jul 17, 2007
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Aquamarine Financial (Cayman) LtdPassive (13G)May 15, 2026
- Bml Investment Partners, L.P.Passive (13G)Feb 9, 2026
- Kidron NadavActivist (13D)Aug 28, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Kidron NadavOfficer — President and CEO | Mar 30, 2026 | Tax withholding | 44,818 | $3.31 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 635,431 | 3.4 | -2.3% |
| Apr 30, 2026 | 650,650 | 4.5 | +12.8% |
| Apr 15, 2026 | 576,933 | 5.9 | +2.5% |
| Mar 31, 2026 | 562,979 | 5.5 | +4.0% |
| Mar 13, 2026 | 541,599 | 3.6 | -2.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or dispositionMar 31, 2026
- Entered a material agreementFeb 20, 2026
- Entered a material agreement · Other material eventJan 14, 2026
- Other material eventJan 7, 2026
- Director / officer changeDec 31, 2025
- Other material eventDec 31, 2025
- Results of operationsNov 17, 2025
- Entered a material agreement · Modified shareholder rightsNov 17, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QQUARTERLY REPORTMay 19, 2026
- NT 10-QNOTIFICATION OF LATE FILINGMay 15, 2026
- SCHEDULE 13GMay 15, 2026
- 3May 14, 2026
- SCHEDULE 13DMay 14, 2026
- 8-KCURRENT REPORTMar 31, 2026
- 4Mar 31, 2026
- 4Mar 31, 2026
- 10-KANNUAL REPORTMar 26, 2026
- 4Mar 18, 2026
- 4Mar 18, 2026
- 4Mar 18, 2026
- 4Mar 18, 2026
- 4Mar 16, 2026
- 8-KFeb 20, 2026
Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.